DOVER, Del., Aug. 5, 2025 /PRNewswire/ -- Diamond Porta Potty, a nationwide provider of portable restrooms, is spotlighting pivotal trends reshaping the portable sanitation...
Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y)
Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS)...
Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.
Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.
Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines,...
The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational...
The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...
High-performance cleaning brand debuts Aloe Glow™ Pet Shampoo and Enzyme Pet Stain & Odor Eliminator—inviting retailers to book meetings in Las Vegas, Aug 13-15
SAN...
ANN ARBOR, Mich., July 30, 2025 /PRNewswire/ -- Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Nature featuring groundbreaking...
-Company expects to initiate Phase 2 study in 2H 2025-
SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company...
LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as...
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea®Upon approval, EYLUXVI® will...
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –